[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-risk-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-risk-bleeding":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100639327","phase-4-investigating-a-personalized-approach-to-anti-platelet-therapy-100639327",false,"NCT07602257","Investigating a Personalized Approach to Anti-Platelet Therapy","Reassessment of Anti-Platelet Therapy Using an Individualized Strategy With Pharmacogenomics to Refine Anti-Platelet Drugs in Vulnerable Patients to Eliminate Thrombotic and Bleeding Complications - A Cluster Randomized Pilot Study","RAPID PREVENT","Inclusion Criteria:\n\n* Age \\>18 years old\n* Receiving PCI with stenting\n\nExclusion Criteria:\n\n* Inability to take ticagrelor\n* Inability to take clopidogrel\n* Not expected to survive \\>48hours\n* Not able to complete a buccal swab","ALL","18 Years",{"count":20,"type":21},1760,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.",[27],"High Risk Bleeding",[29,30,31],"Thrombosis","bleeding complications","Anti-platelet therapy","NOT_YET_RECRUITING","2026-05-15",{"date":35,"type":36},"2026-05-22","ACTUAL",{"date":38,"type":21},"2026-06-01",{"date":40,"type":21},"2029-12-28",{"name":42,"class":43},"Ottawa Heart Institute Research Corporation","OTHER"]